Key terms
About GLPG
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest GLPG news
Mar 08
12:01pm ET
Galapagos price target lowered to EUR 35 from EUR 36 at Morgan Stanley
Mar 06
8:24pm ET
Galapagos assumed with an Equal Weight at Morgan Stanley
Feb 27
6:47am ET
Galapagos price target lowered to $41 from $44 at BofA
Feb 26
8:45pm ET
Galapagos (GLPG) Gets a Hold from RBC Capital
Feb 26
3:22pm ET
Galapagos price target lowered to EUR 33 from EUR 37 at Barclays
Feb 23
2:25pm ET
TD Cowen Sticks to Their Buy Rating for Galapagos (GLPG)
Feb 22
4:04pm ET
Galapagos reports FY23 revenue EUR 543.8M vs EUR 264M last year
Jan 31
4:09pm ET
Galapagos completes transfer of Jyseleca business to Alfasigma
Jan 04
4:03pm ET
Galapagos enters GMP manufacturing agreement with Thermo Fisher
Jan 03
4:05pm ET
Galapagos collaborates with BridGene Biosciences for small molecule drugs
Jan 03
4:04pm ET
BridGene in $27M collaboration and licensing pact with Galapagos
Jan 02
9:04am ET
Galapagos price target raised to $44 from $41 at BofA
Jan 02
5:26am ET
Galapagos signs agreement to transfer Jyseleca business to Alfasigma
Dec 19
4:05pm ET
Galapagos to present new data at Ash 2023 fromongoing CD19 Car-t sudies
No recent news articles are available for GLPG
No recent press releases are available for GLPG
GLPG Financials
Key terms
Ad Feedback
GLPG Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
GLPG Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range